Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia

Ann Hematol. 2014 Dec;93(12):2081-2. doi: 10.1007/s00277-014-2119-8. Epub 2014 May 27.

Authors

Ryusuke Yamamoto¹, Akihiro Yokoyama, Mie Yoneda, Kota Ohashi, Toru Hosoda, Toshiya Kagoo, Saigen Boku, Hironori Ueno, Takahiro Yano

Affiliation

¹ Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo, Japan.

PMID: 24863693
DOI: 10.1007/s00277-014-2119-8

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Azacitidine / therapeutic use*
Drug Evaluation
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Maintenance Chemotherapy*
Male
Middle Aged
Remission Induction
Retrospective Studies
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Azacitidine